Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation shows strong program spending and asset growth, with fluctuating annual revenues and expenses.
EIN: 201082179 · New York, NY · NTEE: V36 · Updated: 2026-03-28
Is Alzheimers Drug Discovery Foundation Legit?
Some Concerns
Assessment based on IRS 990 filings, spending patterns, and AI analysis. Not a guarantee of legitimacy. Full charity check →
Alzheimers Drug Discovery Foundation directs 85% of its spending to programs. This exceeds the industry benchmark of 65%, indicating strong mission focus.
About Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation (EIN: 201082179) is a nonprofit organization based in New York, NY, classified under NTEE code V36. The organization reported total revenue of $56.4M and total assets of $299.4M according to its most recent IRS 990 filing. This transparency report provides an AI-powered analysis of Alzheimers Drug Discovery Foundation's financial health, spending patterns, executive compensation, and overall mission effectiveness based on publicly available IRS data.
AI Transparency Report
Mission Effectiveness Score
NonprofitSpending's AI analysis rates Alzheimers Drug Discovery Foundation with a Mission Score of 90 out of 100 (Excellent). This score reflects the organization's overall financial transparency, program spending efficiency, and governance indicators derived from IRS 990 public filings.
Spending Breakdown
- admin: 10%
- programs: 85%
- fundraising: 5%
According to IRS 990 filings, Alzheimers Drug Discovery Foundation allocates its expenses as follows: admin: 10%, programs: 85%, fundraising: 5%. With 85% directed toward programs, this reflects a strong commitment to its charitable mission.
Executive Compensation Analysis
The organization consistently reports 0% officer compensation across all available filings, which is highly unusual for an organization of its size and financial activity. This suggests that executive leadership may be compensated through other means, or that the organization operates with a unique compensation structure where officers are not directly paid from the organization's funds, which would be a significant positive for resource allocation.
Executive compensation data is sourced from IRS 990 filings, which require nonprofits to disclose the compensation of officers, directors, trustees, and key employees. NonprofitSpending analyzes this data relative to the organization's total revenue and sector benchmarks to assess whether executive pay is reasonable.
Red Flags
The following concerns were identified during AI analysis of Alzheimers Drug Discovery Foundation's IRS 990 filings:
- Inconsistent revenue generation, with significant fluctuations year-over-year (e.g., $254M in 2022 vs. $37.7M in 2023).
- Expenses exceeding revenue in multiple periods (e.g., 2023, 2019, 2017), indicating reliance on reserves or investment income.
Strengths
The following positive indicators were identified for Alzheimers Drug Discovery Foundation:
- Strong program spending ratio, with 85% of expenses dedicated to programs in 2023.
- Significant and consistent growth in assets, from $19.3M in 2014 to $324.1M in 2023, indicating robust financial health.
- Consistent reporting of 0% officer compensation across all filings, suggesting efficient use of funds or unique compensation structure.
- Substantial financial reserves, with assets significantly outweighing liabilities (e.g., $324.1M assets vs. $64.1M liabilities in 2023).
Frequently Asked Questions about Alzheimers Drug Discovery Foundation
Is Alzheimers Drug Discovery Foundation a legitimate charity?
Based on AI analysis of IRS 990 filings, Alzheimers Drug Discovery Foundation (EIN: 201082179) some concerns. Mission Score: 90/100. 2 red flags identified, 4 strengths noted.
How does Alzheimers Drug Discovery Foundation spend its money?
Alzheimers Drug Discovery Foundation directs 85% of its spending to programs and services. The remaining budget covers administration and fundraising costs.
Are donations to Alzheimers Drug Discovery Foundation tax-deductible?
Alzheimers Drug Discovery Foundation is registered as a tax-exempt nonprofit (EIN: 201082179). Donations to most 501(c)(3) organizations are tax-deductible. Consult a tax professional for your specific situation.
Is the Alzheimers Drug Discovery Foundation a good charity?
Based on the provided data, ADDF appears to be a good charity. It consistently allocates a high percentage of its expenses to program services (e.g., 85% in 2023), has shown significant asset growth, and reports 0% officer compensation, indicating a strong focus on its mission and efficient use of funds.
How does ADDF manage its expenses when revenue is lower?
In years where expenses exceed revenue (e.g., 2023 with $61.9M expenses vs. $37.7M revenue, or 2019 with $32.4M expenses vs. $22.7M revenue), ADDF likely draws upon its substantial accumulated assets and prior year surpluses to cover operational costs. The organization's assets grew from $19.3M in 2014 to $324.1M in 2023, providing a significant financial cushion.
What caused the large revenue spike in 2022?
The revenue spike to $254,027,105 in 2022 is a significant outlier compared to other years. While the specific cause isn't detailed in the provided data, it could be attributed to a major one-time donation, a large grant, or a highly successful fundraising campaign during that period.
Filing History
IRS 990 filing history for Alzheimers Drug Discovery Foundation showing financial trends over 13 years of public records:
Over 13 years of IRS 990 filings (2011–2023), Alzheimers Drug Discovery Foundation's revenue has grown by 368.7%, moving from $8.1M to $37.7M. Total assets increased by 4106.1% over the same period, from $7.7M to $324.2M. Total functional expenses rose by 975.1%, from $5.8M to $61.9M. In its most recent filing year (2023), Alzheimers Drug Discovery Foundation reported a deficit of $24.2M, with expenses exceeding revenue. The organization holds $64.2M in liabilities against $324.2M in assets (debt-to-asset ratio: 19.8%), resulting in net assets of $260.0M.
| Year | Revenue | Expenses | Assets | Liabilities | Officer Comp. | |
|---|---|---|---|---|---|---|
| 2023 | $37.7M | $61.9M | $324.2M | $64.2M | — | — |
| 2022 | $254.0M | $36.8M | $340.3M | $56.7M | — | View 990 |
| 2021 | $53.0M | $37.1M | $116.4M | $52.4M | — | View 990 |
| 2020 | $27.6M | $28.3M | $97.4M | $48.1M | — | View 990 |
| 2019 | $22.7M | $32.4M | $97.2M | $47.0M | — | View 990 |
| 2018 | $55.8M | $16.2M | $90.0M | $30.1M | — | View 990 |
| 2017 | $14.5M | $17.8M | $46.0M | $25.7M | — | View 990 |
| 2016 | $23.1M | $17.0M | $45.4M | $21.8M | — | View 990 |
| 2015 | $22.3M | $13.1M | $31.1M | $13.6M | — | View 990 |
| 2014 | $12.0M | $10.0M | $19.3M | $10.8M | — | View 990 |
| 2013 | $9.3M | $7.7M | $14.7M | $8.2M | — | View 990 |
| 2012 | $9.7M | $7.8M | $12.6M | $7.7M | — | View 990 |
| 2011 | $8.1M | $5.8M | $7.7M | $4.6M | — | View 990 |
Year-by-Year Financial Summary
- 2023: Revenue of $37.7M, expenses of $61.9M, and assets of $324.2M (revenue -85.1% year-over-year).
- 2022: Revenue of $254.0M, expenses of $36.8M, and assets of $340.3M (revenue +379.0% year-over-year).
- 2021: Revenue of $53.0M, expenses of $37.1M, and assets of $116.4M (revenue +91.9% year-over-year).
- 2020: Revenue of $27.6M, expenses of $28.3M, and assets of $97.4M (revenue +21.7% year-over-year).
- 2019: Revenue of $22.7M, expenses of $32.4M, and assets of $97.2M (revenue -59.3% year-over-year).
- 2018: Revenue of $55.8M, expenses of $16.2M, and assets of $90.0M (revenue +285.5% year-over-year).
- 2017: Revenue of $14.5M, expenses of $17.8M, and assets of $46.0M (revenue -37.2% year-over-year).
- 2016: Revenue of $23.1M, expenses of $17.0M, and assets of $45.4M (revenue +3.2% year-over-year).
- 2015: Revenue of $22.3M, expenses of $13.1M, and assets of $31.1M (revenue +86.7% year-over-year).
- 2014: Revenue of $12.0M, expenses of $10.0M, and assets of $19.3M (revenue +28.8% year-over-year).
- 2013: Revenue of $9.3M, expenses of $7.7M, and assets of $14.7M (revenue -3.7% year-over-year).
- 2012: Revenue of $9.7M, expenses of $7.8M, and assets of $12.6M (revenue +19.9% year-over-year).
- 2011: Revenue of $8.1M, expenses of $5.8M, and assets of $7.7M.
Data Sources and Methodology
This transparency report for Alzheimers Drug Discovery Foundation is generated by NonprofitSpending's AI analysis engine. The data is sourced from publicly available IRS 990 filings accessed through the ProPublica Nonprofit Explorer API and IRS electronic filing records. The Mission Score, spending breakdown, and other analytical insights are produced by artificial intelligence and should be used as one of multiple factors when evaluating a nonprofit organization.
IRS 990 forms are annual information returns that most tax-exempt organizations must file with the IRS. These forms provide detailed financial information including revenue, expenses, assets, liabilities, and compensation of officers. NonprofitSpending processes this data to provide accessible transparency reports for donors, researchers, and the general public.
Disclaimer
AI-generated analysis based on IRS public records. Not financial or legal advice. Verify information directly with the organization.